GFAP and Alzheimer disease: Plasma biomarkers p-tau181, p-tau217, and GFAP demonstrate clinical utility in distinguishing AD from normal cognition, suggesting that blood-based testing may serve as a feasible screening tool for early identification of AD in very elderly populations.